TABLE 1.
Main clinical trials of bevacizumab in previously untreated patients with advanced nonsmall cell lung cancer
| First author [ref.] | Year(s) | Treatment | Bevacizumab mg·kg−1 | ORR % | PFS months | Overall survival months |
| Johnson [16] | 2004 | Carboplatin+paclitaxel±bevacizumab (6 cycles) |
0 | 18.8 | 4.2 | 14.9 |
| 7.5 | 28.1 | 4.3 | 11.6 | |||
| 15 | 31.5 | 7.4 (p=0.023) |
17.7 (p=0.63) |
|||
| Sandler [17] | 2006 | Carboplatin+paclitaxel±bevacizumab (6 cycles) ±bevacizumab until progression | 0 | 15 | 4.5 | 10.3 |
| 15 | 35 (p<0.001) |
6.2 (p<0.001) |
12.3 (p=0.03) |
|||
| Reck [18, 19] | 2009, 2010 | Cisplatin+gemcitabine±bevacizumab (6 cycles) ±bevacizumab until progression | Placebo | 20.1 | 6.1 | 13.1 |
| 7.5 | 34.1 (p<0.0001) |
6.7 (p=0.003) |
13.6 (p=0.420) |
|||
| 15 | 30.4 (p=0.0023) |
6.5 (p=0.03) |
13.4 (p=0.761) |
ORR: objective response rate; PFS: progression-free survival.